Mitochondrial Heterogeneity in Cancer: A Review

Abstract

Mitochondria are important organelles in nucleated eukaryotic cells that control energy metabolism, redox balance, and apoptosis. Mitochondrial dysfunction, caused by TCA cycle enzyme abnormalities, mitochondrial DNA genetic mutations, a faulty mitochondrial electron transport chain, oxidative stress, or incorrect oncogene and tumor suppressor signaling, has been observed in a variety of human cancers. Emerging research emphasizes the significance of mitochondrial diversity in cancer initiation, progression, and therapy response. This review explores the various elements of mitochondrial variability in cancer, to understand the genetic, functional, and morphological variants. Mechanistically, mitochondrial DNA mutations, metabolic reprogramming, and dynamic changes in mitochondrial shape all contribute to this diversity. Furthermore, we investigate how mitochondrial heterogeneity influences tumor growth, metastasis, and resistance to treatment.A comprehensive and methodical search technique was utilized in the methodology to locate studies across multiple databases. A systematic search was conducted utilizing combinations of keywords such as mitochondrial heterogeneity, Cancer and related terms to access PubMed/MEDLINE, Scopus, Web of Science, and other credible academic databases.Therapeutically, targeting mitochondrial heterogeneity offers intriguing pathways for cancer treatment, with treatments cantered on modifying mitochondrial metabolism, restoring dynamics, and exploiting dysfunction-related vulnerabilities. Understanding mitochondrial variability has the potential to lead to novel therapeutic approaches and individualized treatment techniques, ultimately improving patient outcomes.